Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bioxcel, Calliditas, Histogen, Melinta, Oryzon, Pharmaessentia, Tetra.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adamis, Aeterna Zentaris, Altimmune, Amring, Amzell, Aveo, Astrazeneca, Biovaxys, Bright Minds, Decipher, Destiny, Genevant, Gilead, Horizon, J&J, Lattice, Magenta, Merck, Mersana, Newron, Point, PTC, Resverlogix, Takeda, Tevogen, Timber, Urogen, Veracyte, Viela, Wuxi, Zambon.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aclaris, Amgen, Atara, Atyr, Bioaegis, Bioarctic, Black Diamond, Bluebird, Corcept, Curasen, Edesa, Eisai, Equillium, Galecto, Gamida, Immunitybio, Lilly, Magenta, Moderna, Molecular Partners, Novartis, Ocuphire, Opthea, Ose, Quantum Leap, Regeneron, Rubius, Sernova, Takeda, Tilt, Timber, Tonix, Zenith.

Biopharmas raising money in public or private financings, including: Adial, Alvotech, Bicara, Cytoseek, Finch, Graphite, Insitro, Instil, Savara, VLP.

New hires and promotions in the biopharma industry, including: Alx, Ardelyx, Aulos, Eledon, IGM, Minovia, Modus, Panbela, Reneo, Silverback, Xbrane.

The latest global regulatory news, changes and updates affecting biopharma, including: FDA launches EUA safety dashboard; Fed Circuit claims mandamus jurisdiction in IPR institution; Comment period reopened on Orange Book patents.

Total raised in public, private and other financings of biopharma companies, comparing 2021 vs. 2020 vs. 2019.

Year-to-date money raised in public, private and other financings of biopharma companies.

The top 10 biopharma stock gainers and losers for the week.